课题基金 / 基金详情

PHASE I STUDY OF HIGH DOSE INTERMITTENT CALCITRIOL IN ADVANCED MALIGNANCIES

PHASE I STUDY OF HIGH DOSE INTERMITTENT CALCITRIOL IN ADVANCED MALIGNANCIES
高剂量间歇性骨化三醇治疗晚期恶性肿瘤的 I 期研究
批准号:
6116995
负责人:
WILLIAM D HENNER
金额:
$3.13万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

WILLIAM D HENNER的其他基金

相似基金

相关文献

中文摘要
翻译
1,25-二羟维生素D及其类似物的抗增殖作用 已经在许多组织培养和动物模型中得到证实, 不同的人类癌症间歇性暴露于1,25-二羟维生素D 在体外抑制肿瘤细胞生长, 体内抗增殖作用。 维生素D对人体的毒性, 主要是高钙血症,随着暴露于维生素 D. 他们研究的假设是,间歇给药可能会产生 抗增殖水平的1,25-二羟基维生素D,同时最小化 毒性 这种间歇给药尚未研究, 间歇给予耐受剂量的1,25-二羟维生素D 被定义。 我们试图确定最大耐受剂量和最佳剂量。 间歇性给予骨化三醇的治疗方案。
英文摘要
Antiproliferative effects of 1,25-dihydroxyvitamin D and its analogues have been demonstrated in tissue culture and animal models of many different human cancers. Intermittent exposure to 1,25-dihydroxyvitamin D suppresses neoplastic cell growth in vitro and maybe sufficient to achieve antiproliferative effects in vivo. Toxicity of Vitamin D in humans, principally hypercalcemia, increases with duration of exposure to vitamin D. The hypothesis of they study is that intermittent dosing may produce antiproliferative levels of 1,25-disydroxyvitamin D while minimizing toxicity. Such intermittent dosing has not been studied and maximally tolerated doses of 1,25-dihydroxyvitamin D given intermittently have not been defined. We seek to define the maximally tolerated dose and optimal treatment schedule of Calcitriol delivered intermittently.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pulse calcitriol in patients with rising PSA after treatement for prostate cancer
DNA POLYMORPHISMS & CANCER RISKS
CORE--TUMOR PROCUREMENT
CORE--TUMOR PROCUREMENT
海外基金